Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis

Cancer Immunology, Immunotherapy

Volumn 63, Issue 12, 2014, Pages 1307-1317

  Tucker, Jo A ^a   Jochems, Caroline ^a   Boyerinas, Benjamin ^a   Fallon, Jonathan ^a   Greiner, John W ^a   Palena, Claudia ^a   Rodell, Timothy C ^b   Schlom, Jeffrey ^a   Tsang, Kwong Yok ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GlobeImmune Inc   (United States)

Author keywords

Agonist epitope; Brachyury; Cytotoxic T lymphocytes (CTL); Epithelial to mesenchymal transition (EMT); Immunotherapy; Saccharomyces cerevisiae vector

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; PEPTIDE VACCINE; PERFORIN; RECOMBINANT VACCINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BRACHYURY; UNCLASSIFIED DRUG; BRACHYURY PROTEIN; FETOPROTEIN; T BOX TRANSCRIPTION FACTOR;

ANTIGEN BINDING; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CELL FUNCTION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG ANALYSIS; DRUG IDENTIFICATION; DRUG SYNTHESIS; ENHANCER REGION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOTHERAPY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTASIS; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN SECRETION; SACCHAROMYCES CEREVISIAE; T LYMPHOCYTE; TRANSGENIC MOUSE; ANIMAL; FEMALE; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; EPITOPES, T-LYMPHOCYTE; FEMALE; FETAL PROTEINS; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOPLASMS; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84916220460     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1603-2     Document Type: Article

References (43)

1. Thiery JP (2002) Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454. doi:10.1038/nrc822
2. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117(7):927–939. doi:10.1016/j.cell.2004.06.006
3. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2(2):76–83. doi:10.1038/35000025
4. Hamilton DH, Litzinger MT, Fernando RI, Huang B, Palena C (2012) Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas. Semin Oncol 39(3):358–366. doi:10.1053/j.seminoncol.2012.02.005
5. Kispert A, Koschorz B, Herrmann BG (1995) The T protein encoded by brachyury is a tissue-specific transcription factor. EMBO J 14(19):4763–4772
6. Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP, Schlom J (2007) The human T-box mesodermal transcription factor brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res 13(8):2471–2478. doi:10.1158/1078-0432.CCR-06-2353
7. Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C (2010) The T-box transcription factor brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest 120(2):533–544. doi:10.1172/JCI38379
8. Palena CSJ (2013) Target: brachyury, a master driver of epithelial-to-mesenchymal transition (EMT). In: Marshall J (ed) Cancer therapeutic targets: SpringerReference (www.springerreference.com). Springer, Berlin. doi:10.1007/SpringerReference_3676052014-03-1406:40:12UTC
9. Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, Costarelli L, Litzinger M, Hamilton D, Huang B, Tucker J, Tsang KY, Schlom J, Palena C (2012) Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res 18(14):3868–3879. doi:10.1158/1078-0432.CCR-11-3211
10. Huang B, Cohen JR, Fernando RI, Hamilton DH, Litzinger MT, Hodge JW, Palena C (2013) The embryonic transcription factor brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies. Cell Death Dis 4:e682. doi:10.1038/cddis.2013.208
11. Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, Cavaliere F, Huang B, Fernando RI, Hamilton DH, Jochems C, Tsang KY, Cheng Q, Kim Lyerly H, Schlom J, Guadagni F (2014) Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis. J Natl Cancer Inst 106(5). doi:10.1093/jnci/dju054
12. Haro A, Yano T, Kohno M, Yoshida T, Koga T, Okamoto T, Takenoyama M, Maehara Y (2013) Expression of Brachyury gene is a significant prognostic factor for primary lung carcinoma. Ann Surg Oncol 20(Suppl 3):S509–S516. doi:10.1245/s10434-013-2914-9
13. Pinto F, Pertega-Gomes N, Pereira MS, Vizcaino JR, Monteiro P, Henrique RM, Baltazar F, Andrade RP, Reis RM (2014) T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness. Clin Cancer Res. doi:10.1158/1078-0432.CCR-14-0421
14. Kilic N, Feldhaus S, Kilic E, Tennstedt P, Wicklein D, Wasielewski R, Viebahn C, Kreipe H, Schumacher U (2011) Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer 47(7):1080–1085. doi:10.1016/j.ejca.2010.11.015
15. Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, Boshoff C, Flanagan AM (2006) Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 209(2):157–165. doi:10.1002/path.1969
16. Ellis JM, Henson V, Slack R, Ng J, Hartzman RJ, Katovich Hurley C (2000) Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance of A*02011 and identification of HLA-A*0231. Hum Immunol 61(3):334–340
17. Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C (2013) Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury–yeast vaccine. Oncotarget 4(10):1777–1790
18. Heery CR, Singh H, Marte JL, Madan RA, O’Sullivan Coyne GH, Farsaci B, Rodell TC, Palena C, Schlom J, JL G (2014) NCI experience using yeast–brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma. 2014 ASCO Annual Meeting J Clin Oncol 32:5 s (suppl; abstr 3081)
19. Open label study to evaluate the safety and tolerability of GI-6301 (whole heat-killed recombinant yeast modified to express brachyury protein) in adults with solid tumors (NCT01519817) http://clinicaltrials.gov/show/NCT01519817
20. Singh H, Heery CR, Marte JL, Farsaci B, Madan RA, O’Sullivan Coyne GH, Palena C, Rodell TC, Schlom J, Gulley JL (2014) A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma. J Clin Oncol 32 (suppl; abstr e14026)
21. Grey HM, Ruppert J, Vitiello A, Sidney J, Kast WM, Kubo RT, Sette A (1995) Class I MHC-peptide interactions: structural requirements and functional implications. Cancer Surv 22:37–49
22. Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J (2002) Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin Cancer Res 8(1):41–53
23. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL (2012) Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 13(5):501–508. doi:10.1016/S1470-2045(12)70006-2
24. Vaccine and antibody treatment of prostate cancer (NCT00113984). http://www.clinicaltrials.gov/ct2/show/NCT00113984?term=NCT00113984&rank=1
25. Britten CM, Meyer RG, Kreer T, Drexler I, Wolfel T, Herr W (2002) The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Methods 259(1–2):95–110
26. DeMars R, Rudersdorf R, Chang C, Petersen J, Strandtmann J, Korn N, Sidwell B, Orr HT (1985) Mutations that impair a posttranscriptional step in expression of HLA-A and -B antigens. Proc Natl Acad Sci USA 82(23):8183–8187
27. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152(1):163–175
28. Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D’Amaro J, Kenemans P, Melief CJ, Kast WM (1993) Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 23(6):1215–1219. doi:10.1002/eji.1830230603
29. Cereda V, Poole D, Palena C, Das S, Bera T, Remondo C, Gulley J, Arlen P, Yokokawa J, Pastan I, Schlom J, Tsang K (2010) New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. Cancer Immunol Immunother 59(1):63–71. doi:10.1007/s00262-009-0723-6
30. Yokokawa J, Bera TK, Palena C, Cereda V, Remondo C, Gulley JL, Arlen PM, Pastan I, Schlom J, Tsang KY (2007) Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). Int J Cancer 121(3):595–605. doi:10.1002/ijc.22698
31. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J (1995) Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87(13):982–990
32. Jochems C, Tucker JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, Tsang KY (2014) Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. Cancer Immunol Immunother 63(2):161–174. doi:10.1007/s00262-013-1494-7
33. Remondo C, Cereda V, Mostbock S, Sabzevari H, Franzusoff A, Schlom J, Tsang KY (2009) Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen. Vaccine 27(7):987–994. doi:10.1016/j.vaccine.2008.12.002
34. Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, Schlom J, Tsang KY (2005) Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res 11(17):6342–6351. doi:10.1158/1078-0432.ccr-05-0596
35. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW (1991) Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 173(4):1007–1015
36. Irwin MJ, Heath WR, Sherman LA (1989) Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response. J Exp Med 170(4):1091–1101
37. Hamann D, Kostense S, Wolthers KC, Otto SA, Baars PA, Miedema F, van Lier RA (1999) Evidence that human CD8 + CD45RA + CD27- cells are induced by antigen and evolve through extensive rounds of division. Int Immunol 11(7):1027–1033
38. Plunkett FJ, Franzese O, Finney HM, Fletcher JM, Belaramani LL, Salmon M, Dokal I, Webster D, Lawson AD, Akbar AN (2007) The loss of telomerase activity in highly differentiated CD8 + CD28-CD27-T cells is associated with decreased Akt (Ser473) phosphorylation. J Immunol 178(12):7710–7719
39. Hamilton DH, Huang B, Fernando RI, Tsang KY, Palena C (2014) WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. Cancer Res 74(9):2510–2519. doi:10.1158/0008-5472.CAN-13-1894
40. Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, Madan RA (2014) Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother 63(3):225–234. doi:10.1007/s00262-013-1505-8
41. Bernstein MB, Chakraborty M, Wansley EK, Guo Z, Franzusoff A, Mostbock S, Sabzevari H, Schlom J, Hodge JW (2008) Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine 26(4):509–521. doi:10.1016/j.vaccine.2007.11.033
42. Wansley EK, Chakraborty M, Hance KW, Bernstein MB, Boehm AL, Guo Z, Quick D, Franzusoff A, Greiner JW, Schlom J, Hodge JW (2008) Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res 14(13):4316–4325. doi:10.1158/1078-0432.CCR-08-0393
43. A phase 2 study of GI-6207 in patients with recurrent medullary thyroid cancer (NCT01856920). http://clinicaltrials.gov/ct2/show/NCT01856920?term=NCT01856920&rank=1